goldennet

Search

Please select the unit you wish to search and enter the keyword in the text field below.

  • PRESSROOM
  • PUBLICATIONS
  • PIPELINE
  • TECHNOLOGY
  • Leave TLC website?

    You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.{br}{br}Click “STAY” to return to tlcbio.com or “CONTINUE” to proceed.

    STAY
    CONTINUE

    TLC504

    LNP NSAID

    Description

    LNP NSAID for local pain relief

    Development Status

    Preclinical

    Advantages

    • Extended release
    • Works locally to reduce systemic exposure
    • Bypasses the digestive system to avoid gastrointestinal issues
  • Overview
  • Overview

    TLC504 is a non-steroidal anti-inflammatory drug (NSAID) developed by TLC BioSciences, designed to provide pain relief with its innovative local anti-inflammatory and analgesic properties. Encapsulated in lipid nanoparticles (LNP), TLC504 ensures targeted delivery to inflamed tissues, offering a new level of precision in pain management. This advanced formulation aims to reduce systemic exposure and potential side effects, marking a significant advancement in therapeutic pain treatments.

    Indication

    Preclinical
    Phase 1
    Phase 2
    Phase 3
    NDA
    Market

    Inflammation & pain

    Preclinical ongoing